Company
Intellisense & Cognisense Technology (ICT) Limited was established in January 2025 and is headquartered in Hong Kong. It is an innovative biotechnology company dedicated to revolutionising personal health monitoring methods. As a pioneer in biomarker sensing technology, the company focuses on developing the next generation of wearable and portable biosensors, providing global users with accurate, convenient, and non-invasive health management solutions.
The company's core technology is based on a self-developed organic electrochemical transistor sensing platform. The first-generation saliva glucose sensor developed boasts significant advantages, including high sensitivity (detection limits at the nanomolar level), strong selectivity (excellent anti-interference performance), and low-cost mass production. Currently, our products enable real-time dynamic monitoring of key metabolites such as glucose, uric acid, and lactic acid, and can be widely applied in areas such as chronic disease management, daily health monitoring, and life sciences research.
Adhering to the philosophy of "Empowering Health through Technology," ICT Limited is committed to providing intelligent and personalised health solutions through innovative non-invasive monitoring technologies for chronic disease patients, health management populations, and research institutions. Our mission is to make health monitoring as easy as breathing, allowing everyone to effortlessly grasp their health data. Looking ahead, ICT Limited will continue to invest in research and development, driving innovations in health monitoring technology and contributing to the vision of "Healthy China 2030," collectively building a smarter and healthier future world.
Description
Intellisense & Cognisense Technology Limited is an innovative biotechnology company focused on developing advanced methods for personal health monitoring
